-
-
-
-
-
-
-
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
-
-
-
-
-
-
-
CervoMed raises $10.5 million, seeks partnership for dementia drug
-
-
-
-
-
-
-
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-
-
-
-
-
-
-
-
CervoMed reports positive Phase 2b trial results for dementia treatment
-
-
-
-
-
-
-
CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies
-
-
-
-
-
-
-
CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference
-
-
-
-
-
-
-
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
-
1,177,784 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

